Aurinia Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
85.32 M |
Public Float |
- |
Aurinia Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.71 |
Market Cap |
$591.12 M |
Shares Outstanding |
84.48 M |
Public Float |
- |
Aurinia Pharmaceuticals Inc. | |
Stock Exchange | Toronto Stock Exchange Prices |
EPS |
CAD0.94 |
Market Cap |
CAD770.74 M |
Shares Outstanding |
78.45 M |
Public Float |
52.94 M |
Address |
4464 Markham Street Victoria British Columbia V8Z 7X8 Canada |
Employees | - |
Website | http://www.auriniapharma.com |
Updated | 07/08/2019 |
Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada. . |